Dabrafenib/trametinib treatment helps melanoma cells escape from the microenvironment, which may be a predictor of the effectiveness of dual BRAF/MEK (mitogen-activated protein kinase kinase) inhibitors in treating melanoma (28). Here, WNK2 is linked to melanoma.